Share This Article:

One-month immunotherapy trial in treatment-failed TB patients

Abstract Full-Text HTML Download Download as PDF (Size:106KB) PP. 50-55
DOI: 10.4236/oji.2011.12006    5,653 Downloads   12,786 Views   Citations

ABSTRACT

reatment failed TB patients have very limited chances of survival. Open label trial of daily oral pill of V-5 Immunitor (V5) was conducted in 48 treatment-failed TB patients on palliative support consisting of isoniazid (H) and rifampicin (R). The subjects had the following forms of TB; cavitary: disseminated: MDR-TB: DR-TB: TB/HIV at 35:13:7:4:1 ratio. After 1 month 62.5% of V5-treated patients experienced negative sputum smear conversion (P < 0.0001), comprising 11 out of 12 (91.7%) converted among those who had drug-resistant TB and TB/HIV. TB-associated inflammation was downregulated as evidenced by normalization of leukocytosis 7.4 vs. 6.7 x 109 L (P = 0.01) and decreased erythrocyte sedimentation rate 20.5 vs. 14.9 mm/h (P < 0.0001). The mean body temperature normalized from 37.25° ± 0.6° to 36.98° ± 0.4° (P = 0.0002). The average body weight gain and body mass index (BMI) increased by 0.8 ± 0.7 kg and from 18.9 to 19.6 kg/m2 respectively (P < 0.0001). Two patients (4.2%) died from illicit drug- and alcohol-abuse related causes. No adverse effects or reactivation of disease due to immune intervention were seen at any time. V5 is safe and in combination with a simple two-drug regimen was highly effective as an immune adjunct to produce favorable outcome among treatment-failed and/ or drug-resistant TB patients.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Arjanova, O. , Butov, D. , Prihoda, N. , Zaitzeva, S. , Yurchenko, L. , Sokolenko, N. , Stepanenko, A. , Butova, T. , Grinishina, E. , Maksimenko, O. , Jirathitikal, V. , Bourinbaiar, A. , Frolov, V. and Kutsyna, G. (2011) One-month immunotherapy trial in treatment-failed TB patients. Open Journal of Immunology, 1, 50-55. doi: 10.4236/oji.2011.12006.

References

[1] Lienhardt, C., Vernon, A. and Raviglione, M.C. (2010) New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine, 16, 186-193. doi:10.1097/MCP.0b013e328337580c
[2] Tiemersma, E.W., van der Werf, M.J., Borgdorff, M.W., Williams, B.G. and Nagelkerke, N.J. (2011) Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS One, 6, e17601. doi:10.1371/journal.pone.0017601
[3] Goble, M., Iseman, M.D., Madsen, L.A., Waite, D., Ackerson, L. and Horsburgh, C.R. Jr. (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New England Journal of Medicine, 328, 527-532. doi:10.1056/NEJM19930225328080
[4] Churchyard, D.J. (2007) Report of the expert consultation on immunotherapeutic interventions for tuberculosis. TDR/World Health Organization, Geneva, Switzerland. http://apps.who.int/tdr/publications/tdr-research-publications/immunotherapeutic-interventions-tb/pdf/interventions-tb.pdf
[5] Batdelger, D., Dandii, D., Jirathitikal, V. and Bourinbaiar, A.S. (2007) Open label trial of therapeutic hepatitis B vaccine V-5 Immu-nitor (V5) delivered by oral route. Letters in Drug Design and Discovery, 4, 540-544, 2007. doi:10.2174/157018007782794545
[6] Batdelger, D., Dandii, D., Jirathitikal, V. and Bourinbaiar, A.S. (2008) Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine, 26, 2733-2737. doi:10.1016/j.vaccine.2008.03.021
[7] Batdelger, D., Dandii, D., Dahgwahdorj, Ya., Erdenetsogt, E., Oyunbileg, J., Tsend, N., Bayarmagnai, B., Jirathitikal, V. and Bourin-baiar, A.S. (2009) Clinical experience with therapeutic vaccines designed for patients with hepatitis. Current Pharmaceutical Design, 15, 1159-1171. doi:10.2174/138161209787846793
[8] Arjanova, O.V., Prihoda, N.D., Yurchenko, L.V., Sokolenko, N.I., Frolov, V.M., Tarakanovskaya, M.G., Jirathitikal, V. and Bourin-baiar, A.S. (2010) Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. Journal of Vaccines and Vaccination, 1, 103. doi:10.4172/2157-7560.1000103
[9] Butov, D.A., Pashkov, Y.N., Stepanenko, A.L., Choporova, A.I., Butova, T.S., Batdelger, D., Jirathitikal, V., Bourinbaiar, A.S. and Zaitzeva, S.I. (2011) Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi- drug-resistant (MDR) TB. Journal of Immune Based Therapies and Vaccines, 9, 3. doi:10.1186/1476-8518-9-3
[10] Arjanova, O.V., Prihoda, N.D., Yurchenko, L.V., Sokolenko, N.I., Frolov, V.M., Tarakanovskaya, M.G., Batdelger, D., Jirathitikal, V. and Bourinbaiar, A.S. (2011) Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Im-munotherapy, 3, 181-191. doi:10.2217/imt.10.96
[11] Nuermberger, E.L., Spigelman, M.K. and Yew, W.W. (2010) Current development and future prospects in chemotherapy of tubercu-losis. Respirology, 15, 764-778. doi:10.1111/j.1440-1843.2010.01775.x
[12] Becerra, M.C., Freeman, J., Bayona, J., Shin, S.S., Kim, J.Y., Furin, J.J., Werner, B., Sloutsky, A., Timperi, R., Wilson, M.E., Pagano, M. and Farmer, P.E. (2000) Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Diseases, 4, 108-114. PMid:10694087
[13] Johnston, J.C., Shahidi, N.C., Sadatsafavi, M. and Fitzgerald, J.M. (2009) Treatment outcomes of multidrug- resistant tuberculosis: a systematic review and meta- analysis. PLoS One, 4, e6914. doi:10.1371/journal.pone.0006914
[14] Faustini, A., Hall, A.J. and Perucci, C.A. (2005) Tuber- culosis treatment outcomes in Europe: a systematic re- view. European Res-piratory Journal, 26, 503-510. doi:10.1183/09031936.05.00103504
[15] Khan, A., Sterling, T.R., Reves, R., Vernon, A. and Horsburgh, C.R. (2006) Lack of weight gain and relapse risk in a large tuberculo-sis treatment trial. American Journal of Respiratory and Critical Care Medicine, 174, 344-348. doi:10.1164/rccm.200511-1834OC
[16] Bernabe-Ortiz, A., Carcamo, C.P., Sanchez, J.F. and Rios, J. (2011) Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. PLoS One, 6, e18474. doi:10.1371/journal.pone.0018474
[17] Zafran, N., Heldal, E., Pavlovic, S., Vuckovic, D. and Boe, J. (1994) Why do our patients die of active tuberculosis in the era of ef-fective therapy? Tuberculosis and Lung Disease, 75, 329-333. doi:10.1016/0962-8479(94)90077-9
[18] Franke, M.F., Appleton, S.C., Bayona, J., Arteaga, F., Palacios, E., Llaro, K., Shin, S.S., Becerra, M.C., Murray, M.B. and Mitnick, C.D. (2008) Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clinical Infectious Diseases, 46, 1844-1851. doi:10.1086/588292
[19] Akintunde, E.O., Shokunbi, W.A. and Adekunle, C.O. (1995) Leucocyte count, platelet count and erythrocyte sedimentation rate in pulmonary tuberculosis. African Journal of Medicine and Medical Science, 24, 131-134. PMid:8669390
[20] Barnes, P.F. (2003) Immunotherapy for tuberculosis: wave of the future or tilting at windmills? American Journal of Respiratory and Critical Care Medicine, 168, 142-143. doi:10.1164/rccm.2305001
[21] Churchyard, GJ, Kaplan, G, Fallows, D, Wallis, RS, Onyebujoh, P. and Rook, GA. (2009) Advances in immunotherapy for tuberculo-sis treatment. Clinical Chest Medicine, 30, 769-782. doi:10.1016/j.ccm.2009.08.009
[22] Dheda, K., Schwander, S.K., Zhu, B., van Zyl-Smit, R.N. and Zhang, Y. (2010) The immunology of tuberculosis: from bench to bed-side. Respirology, 15, 433-450. doi:10.1111/j.1440-1843.2010.01739.x
[23] Grange, J.M., Brunet, L.R. and Rieder, H.L. (2011) Immune protection against tuberculosis-when is immunotherapy preferable to vaccination? Tuberculosis, 91, 179-185. doi:10.1016/j.tube.2010.12.004
[24] Silin, D.S., Lyubomska, O.V., Ershov, F.I., Frolov, V.M. and Kutsyna, G.A. (2009) Immunomodulators with interferon inducing properties. Current Pharmaceutical Design, 15, 1238-1247. doi:10.2174/138161209787846847
[25] Arjanova, O.V., Prihoda, N.D., Sokolenko, N.I., Yurchenko, L.V., Vihrova, L.A., Pylypchuk, V.S., Frolov, V.M. and Kutsyna, G.A. (2009) Impact of adjunct immunotherapy with multi-herbal supplement Dzherelo (Immunoxel) on treatment outcomes in end-stage TB/HIV patients. Journal of Antivirals and Antiretrovirals, 1, 86-88. doi:10.4172/jaa.1000013
[26] Stanford, J., Stanford, C. and Grange, J. (2004) Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Fron-tiers in Bioscience, 9, 1701-1719. doi:10.2741/1292

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.